Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. J. Pharm. Sci. (Online) ; 58: e191140, 2022. tab
Artigo em Inglês | LILACS | ID: biblio-1394053

RESUMO

Abstract The study aimed to assess possible spirulina effects on lipid profile, glucose, and malondialdehyde levels in new cases of type 2 diabetes. The subjects consisted of 30 new cases of types 2 diabetes that divided into two groups; each consisted of 15 diabetic patients. Group I did not take any functional food or supplement and received no spirulina supplementation. Group II or experimental group also did not take any functional food or supplement but received spirulina supplementation. Analysis of data was done using SPSS 16.0. The Kolmogorov-Smirnov test, paired t-test, Wilcoxon test, and Spearman correlation analysis were used to analyze the data. After eight weeks of spirulina supplementation, significant differences were shown in the serum levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and malondialdehyde. The serum fasting blood glucose, lipid profiles, and malondialdehyde levels at baseline were negatively and positively correlated with changes in these parameters. Spirulina supplementation may have a beneficial effect on lipid profile and malondialdehyde (MDA) levels through an interventional 8 weeks. This effect may protect subjects against free radicals and the development of some diseases such as atherosclerosis. The spirulina supplementation also showed a potential lipid-lowering effect on new case type 2 diabetic patients which may help the diabetics to have control on lipid levels. In addition, spirulina may be used as a functional food for the management of lipid profiles and MDA levels.


Assuntos
Pacientes/classificação , Diabetes Mellitus Tipo 2/patologia , Spirulina/classificação , Glucose/administração & dosagem , Malondialdeído/administração & dosagem
2.
Braz. j. infect. dis ; 18(5): 487-490, Sep-Oct/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-723077

RESUMO

Background: This study performed at the National Research Institute of Tuberculosis and Lung Disease, Tehran, Iran, aimed to evaluate the effect of concomitant pulmonary hypertension on the outcome of pulmonary tuberculosis. Methods: New cases of pulmonary tuberculosis were recruited for the study. Pulmonary hypertension was defined as systolic pulmonary arterial pressure ≥35 mm Hg estimated by transthoracic Doppler echocardiography. We assessed the relationship between pulmonary hypertension and mortality during the six-month treatment of tuberculosis. Results: Of 777 new cases of pulmonary tuberculosis, 74 (9.5%) had systolic pulmonary arterial pressure ≥35 mm Hg. Ten of them (13.5%) died during treatment compared to 5% of cases with pulmonary arterial pressure less than 35 mm Hg (p = 0.007). Logistic regression analysis showed that pulmonary hypertension and drug abuse remained independently associated with mortality (OR = 3.1; 95% CI: 1.44–6.75 and OR = 4.4; 95% CI: 2.35–8.17, respectively). Conclusion: A significant association was found between mortality and presence of pulmonary hypertension and drug abuse among new cases of pulmonary tuberculosis. .


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Hipertensão Pulmonar/mortalidade , Tuberculose Pulmonar/mortalidade , Diagnóstico Precoce , Ecocardiografia Doppler , Hipertensão Pulmonar/etiologia , Hipertensão Pulmonar , Irã (Geográfico)/epidemiologia , Prognóstico , Estudos Retrospectivos , Transtornos Relacionados ao Uso de Substâncias/complicações , Tuberculose Pulmonar/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA